SIMULTANEOUS QUANTIFICATION OF TRAVOPROST AND TIMOLOL MALEATE IN PHARMACEUTICAL FORMULATION BY RP-HPLC

Travoprost and Timolol Maleate are used in treatment of glaucoma by decreasing intra ocular pressure. The present study was designed to develop and validate a simple, sensitive, precise, and specific reverse phase high-performance liquid chromatographic (HPLC) method for simultaneous determination of Travoprost and Timolol maleate in ophthalmic dosage form. Chromatographic separation of these two drugs was achieved on Hypersil BDS C18 column (250 x 4.6 mm, 5 μm) as stationary phase with a mobile phase Water (pH2 adjusted with OPA): Methanol (85:15% v/v) at a flow rate of 0.8 ml/min and PDA detection at 233 nm. The method was carried out at 40oC. The retention times of Timolol maleate and Travoprost were found to be 2.48±0.01 min, 5.10±0.1min respectively. The proposed method was validated for system suitability, linearity, accuracy, precision, LOD, LOQ and robustness. The calibration curves were linear in the concentration range of 25% to 150% of the working concentration (r2 = 0.999) for both the drugs in binary mixture. The LOD was found to be 0.002 μg/ml and 0.244μg/ml and LOQ was found to be 0.007μg/ml and 0.814μg/ml for Travoprost and Timolol maleate respectively. Hence the proposed RP-HPLC method of analysis can be used in quality control departments with respect to routine analysis of ophthalmic drops containing Travoprost and Timolol maleate